Levamisole in multiple sclerosis, with special reference to immunological parameters

Authors:

Abstract
Nineteen patients with multiple sclerosis (MS) were given 1 course of levamisole therapy, and 16 patients were given 2 courses of levamisole treatment in daily dosages of 100-150 mg over 2 periods lasting from 1 mo. to 22 wk each. Clinical effect was evaluated using Kurtzke''s disability status scale. Immediate clinical evaluation showed that 15 patients remained unchanged, 2 improved and 2 became worse. Follow-up revealed after 4-14 mo. that another 4 patients deteriorated and none improved. Altogether 10 patients developed 13 relapses. During this brief therapy, no convincing conclusions were drawn regarding an influence upon the course of the disease, although there was the suggestion that levamisole was not beneficial in MS patients. There was no statistically significant effect of levamisole on peripheral blood lymphocyte count, lymphocyte stimulation tests, leukocyte migration inhibition tests, short and long incubation E[erythrocyte]-rosette forming cells and serum Ig[immunoglobulin]A, IgG or IgM levels. A group of MS patients showed after 1 mo. of levamisole treatment short-lasting restored or potentiated skin hypersensitivity to bacterial and fungal antigens (P < 0.05).